June 22, 2020
We are excited for the launch of the expanded RNA Library Preparation product portfolio. The new enhancements deliver solutions for studying RNA that provide rapid turn-around time, broad study flexibility and sequencing scalability, while delivering exceptional data quality for infectious disease, oncology and genetic disease research.
Building on existing TruSeq™ and Bead-Linked Transposome technologies, the three new kits support a number of methods that allow researchers to discover, characterize and quantify RNA. Specifically, these new offerings include:
- Illumina Stranded Total RNA Prep with Ribo-Zero Plus offers comprehensive analysis of the transcriptome, accurately measures gene and transcript abundance and detects both known and novel coding features and multiple forms of noncoding RNA.
- Illumina Stranded mRNA Prep quantifies gene expression, identifies known and novel isoforms in the coding transcriptome and measures allele-specific expression.
- Illumina RNA Prep with Enrichment enables cost-effective RNA exome analysis using sequence-specific capture of the coding regions of the transcriptome and is ideal for formalin-fixed paraffin-embedded (FFPE) samples.
Illumina Stranded Total RNA Prep enables precise measurement of strand orientation, uniform coverage and high-confidence discovery of features such as alternative transcripts, gene fusions and allele-specific expression. It is compatible with the Ribo-Zero Plus rRNA Depletion Kit that enables highly effective removal of interfering rRNA from multiple species, including human, mouse, rat and bacteria. The Stranded mRNA Prep Kit supports low sample input requirements for highly accurate measurement of gene expression. Targeted RNA sequencing is particularly important in infectious disease research. The new Illumina RNA prep with Enrichment is compatible with the Illumina Respiratory Virus Panel that provides a rapid, streamlined and scalable enrichment solution for targeting respiratory viruses.
“Like many viral pathogens, SARS-CoV-2 does not have a DNA form," said Gary Schroth, Vice President and Distinguished Scientist at Illumina. "Therefore, RNA sequencing technologies have played a critical role in discovering the first novel SARS-CoV-2 genome, enabling diagnostic tests to be rapidly developed and continues to play a pivotal role in characterizing the dynamics, breadth and evolution of the virus. The new RNA-Seq portfolio provides researchers with the most state-of-the-art library prep tools available for infectious disease studies.”
“The new RNA Library Prep solutions improve on the trusted TruSeq products to enable researchers to continue to accelerate discovery with faster, easier-to-use workflows, greater study flexibility and scalability,” said Jim Godsey, Vice President of Clinical Genomics Product Development at Illumina.
The lineup of RNA kits is available for order now on www.Illumina.com.
